Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of LX4211 400 mg Tablet vs 2x200 mg Tablets
NCT02373046Phase 1Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Feb 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotagliflozin in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: Area Under the Curve and Urinary Glucose Excretion at Day 9. Started Feb 2015; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02373046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02373046.